Skip to main content
Caplight Logo









CTCELLS

CTCELLS

Private
DaeguTelecommunications & Networkinghttps://www.ctcells.com/

Last Round

Series B

Extension

Apr 1, 2026

Total Funding Raised

$15.39M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

CTCELLS is a life sciences company that develops cancer diagnostics and cell-based immunotherapy solutions, including liquid biopsy platforms and NK cell-based therapeutics.

Sector

Telecommunications & Networking

Verticals

Consumer Electronics, Internet Providers, Wireless Infrastructure, E-commerce

Business Model

B2B

Customer Profile

Services & Consulting, Hardware Sales

AI Layer

Non-AI

Keywords

cancer diagnosticsliquid biopsycirculating tumor cell isolationCTC isolationbiotech instrumentationmicrofluidicsimmunocytochemistryprotein engineeringcell-based therapeuticsbispecific antibody engineeringclinical research toolslab-on-a-chipprecision medicinebiotech R&D

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

CTCELLS Comparables

Compare CTCELLS with similar companies based on industry and business-model similarity.

CTCELLS comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Menarini Group
71%

CTCELLS Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series B ExtensionApr 1, 2026
Series BMar 22, 2022
GrantJun 22, 2021
Series AApr 21, 2021

Key People

Founding team and executive leadership

Jungmin Lee

Chief Executive Officer

Executive Team

Minseok S. Kim

Founder and CEO

Founding Team

CTCELLS Investors

Notable investors and investment history

CTCELLS investors
InvestorRounds
InterVestSeries B
UTC InvestmentSeries A, Series B
KISEDGrant
KB SecuritiesSeries A
Mirae Asset CapitalSeries B
Enlight VenturesSeries A, Series B
LSK InvestmentSeries A, Series B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 1, 2026

    Raised $6.63M in a Series B Extension round.

  • Nov 13, 2025

    Grew 43% QoQ from 7 to 10 employees.

CTCELLS Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

CTCELLS Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about CTCELLS's valuation, stock price, and market status.

Firmographic Details

HeadquartersDaegu
Employee Range13
Year Founded2018
Last FundingApr 1, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?